Notice Number: NOT-AR-19-036
Key Dates
Release Date : February 20, 2019
RFA-AR-19-028
Issued by
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Purpose
The purpose of this Notice is to amend RFA-AR-19-028 "HEAL Initiative: Back Pain Consortium (BACPAC) Research Program Technology Research Sites (UH2/UH3 Clinical Trial Optional).” The following sections have been modified:
Part 2. Full Text of Announcement
Section I. Funding Opportunity Description
Technology Research Sites
Research Objectives
Currently reads:
The following are non-responsive to this RFA and will not be reviewed:
- Biomarker discovery or validation
- Development of new drugs
- Research involving the use of animal models is not excluded; however, any proposed animal model(s) must be highly relevant to human conditions and the demonstrated application to humans must be included in the specific aims of the proposed project(s).
- Technology development focused on metastatic bone disease or chronic low back pain due to acute or chronic infection or acute trauma.
The following are non-responsive to this RFA and will not be reviewed:
- Development of new drugs.
- Research involving the use of animal models is not excluded; however, any proposed animal model(s) must be highly relevant to human conditions and the demonstrated application to humans must be included in the specific aims of the proposed project(s).
- Technology development focused on metastatic bone disease or chronic low back pain due to acute or chronic infection or acute trauma.
All other aspects of this FOA remain unchanged.
Inquiries
Please direct all inquiries to:
Xincheng Zheng, M.D., Ph.D.
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Telephone: 301-594-4953
Email: [email protected]
and Human Services (HHS)
